# Dossier: CMC PHARMACEUTICALS, INC.

## SBIR Award Details

**Award Title:** N/A

**Amount:** $662,558.64

**Award Date:** 2023-06-27

**Branch:** CBD

## AI-Generated Intelligence Summary

**Company Overview:**

CMC Pharmaceuticals, Inc., based in Neptune, New Jersey, is not a defense or aerospace company. It is a contract development and manufacturing organization (CDMO) focused on providing comprehensive pharmaceutical development and manufacturing services, with a specialization in complex injectables, including sterile fill/finish capabilities. Their core mission appears to be accelerating drug development and ensuring reliable supply for pharmaceutical companies, particularly those with challenging injectable formulations. They aim to solve the problems associated with bringing complex and sterile injectables to market, including formulation development, analytical testing, scale-up, and commercial manufacturing. Their unique value proposition lies in their expertise in handling difficult-to-manufacture injectables, often requiring specialized equipment and techniques, coupled with a full-service CDMO offering.

**Technology Focus:**

* Specializes in sterile fill/finish manufacturing, including vials and pre-filled syringes, with a focus on complex formulations such as liposomes, suspensions, and nano-particles.
* Offers aseptic processing capabilities with advanced isolator technology for enhanced sterility assurance.

**Recent Developments & Traction:**

* Announced a $100 million expansion in 2021, adding a new manufacturing line at its Neptune, NJ facility to increase its capacity for aseptic fill-finish services.
* In 2023, CMC Pharmaceuticals was acquired by Singula Bio B.V., a Dutch life sciences company.
* Continues to participate in industry conferences related to pharmaceutical manufacturing and CDMO services, showcasing capabilities and expertise.

**Leadership & Team:**

While specific individual names for CMC Pharmaceuticals leadership are challenging to ascertain publicly beyond general mentions of executive leadership, the company has been under the leadership of Singula Bio B.V. since their acquisition in 2023. Prior to the acquisition, the company was led by executives experienced in the pharmaceutical manufacturing and CDMO industries.

**Competitive Landscape:**

Primary competitors include:

* Recipharm: Offers a broad range of CDMO services, including injectables, and has a significant global presence.
* Catalent: A large, well-established CDMO with extensive capabilities in sterile injectables manufacturing.

CMC Pharmaceuticals differentiates itself through its specialized focus on complex injectables and its responsiveness as a mid-sized CDMO, allowing for potentially more agile service and customized solutions compared to larger competitors.

**Sources:**

* [https://www.cmcpharmaceuticals.com/](https://www.cmcpharmaceuticals.com/)
* [https://www.njeda.com/in-the-news/cmc-pharmaceuticals-expansion-project-secures-state-support/](https://www.njeda.com/in-the-news/cmc-pharmaceuticals-expansion-project-secures-state-support/)
* [https://www.biopharmadive.com/press-release/20230525/Singula-Bio-completes-acquisition-of-CMC-Pharmaceuticals/](https://www.biopharmadive.com/press-release/20230525/Singula-Bio-completes-acquisition-of-CMC-Pharmaceuticals/)